Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications
Publication partner logo
Publication partner link
https://www.promega.co.uk

Quantifying CDK inhibitor selectivity in live cells.

  • Read more about Quantifying CDK inhibitor selectivity in live cells.

Wells, C. I., Vasta, J. D., Corona, C. R., Wilkinson, J., Zimprich, C. A., Ingold, M. R., ... Robers, M. B. (2020). Quantifying CDK inhibitor selectivity in live cells. Nature communications, 11(1), 2743.

Design, Synthesis and Characterization of Covalent KDM5 Inhibitors.

  • Read more about Design, Synthesis and Characterization of Covalent KDM5 Inhibitors.

Vazquez-Rodriguez, S., Wright, M., Rogers, C. M., Cribbs, A. P., Velupillai, S., Philpott, M., … Brennan, P. E. (2018). Design, Synthesis and Characterization of Covalent KDM5 Inhibitors. Angewandte Chemie (International ed. in English),58(2), 515–519.

Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement

  • Read more about Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement

Vasta, J. D., Corona, C. R., Wilkinson, J., Zimprich, C. A., Hartnett, J. R., Ingold, M. R., … Robers, M. B. (2018). Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. Cell Chemical Biology, 25(2), 206–214.e11.

Subscribe to Promega
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility